PE20001299A1 - Bromhidrato de eletriptan monohidratado - Google Patents

Bromhidrato de eletriptan monohidratado

Info

Publication number
PE20001299A1
PE20001299A1 PE1999001178A PE00117899A PE20001299A1 PE 20001299 A1 PE20001299 A1 PE 20001299A1 PE 1999001178 A PE1999001178 A PE 1999001178A PE 00117899 A PE00117899 A PE 00117899A PE 20001299 A1 PE20001299 A1 PE 20001299A1
Authority
PE
Peru
Prior art keywords
eletriptan
bromhydrate
water
monohydrated
monohydrate
Prior art date
Application number
PE1999001178A
Other languages
English (en)
Inventor
Christopher Ian Dallman
Ronald James Ogilvie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20001299A1 publication Critical patent/PE20001299A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lasers (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE BROMHIDRATO DE ELETRIPTAN MONOHIDRATADO DE FORMULA I; (3-[1-METILPIRROLIDIN-2(R)-IL]METIL)-5-(2-FENILSULFONILETIL)-1H-INDOL) Y A PROCEDIMIENTOS PARA LA PREPARACION COMO: 1)TRATAR UNA SOLUCION DE ELETRIPTAN EN AGUA O UN DISOLVENTE ORGANICO TAL COMO TETRAHIDROFURANO O ACETONA Y FACILITAR LA FORMACION DEL MONOHIDRATO DESEADO CON ACIDO BROMHIDRICO; 2)CRISTALIZAR CUALQUIER FORMA DE BROMHIDRATO DE ELETRIPTAN O MEZCLAS DE LA MISMA, EN AGUA O UN DISOLBVENTE ORGANICO QUE CONTENGA UNA CANTIDAD SUFICIENTE DE AGUA PARA FACILITAR LA FORMACION DEL MONOHIDRATO DESEADO; 3)DESHIDRATAR CUALQUIER FORMA HIDRATADA DE BROMHIDRATO DEL ELETRIPTAN O UNA MEZCLA DE LA MISMA. EL BROMHIDRATO DE ELETRIPTAN MONOHIDRATADO ES UN AGONISTA SELECTIVO DEL RECEPTOR 5-HT1 POR LO QUE PUEDE SER UTIL PARA TRATAR LA MIGRANA, MIGRANA RECURRENTE, HIPERTENSION, DEPRESION, EMESIS, ANSIEDAD, TRASTORNOS DE ALIMENTACION, OBESIDAD, ABUSO DE FARMACOS
PE1999001178A 1998-11-27 1999-11-23 Bromhidrato de eletriptan monohidratado PE20001299A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9825988.0A GB9825988D0 (en) 1998-11-27 1998-11-27 Indole derivatives

Publications (1)

Publication Number Publication Date
PE20001299A1 true PE20001299A1 (es) 2000-12-01

Family

ID=10843140

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001178A PE20001299A1 (es) 1998-11-27 1999-11-23 Bromhidrato de eletriptan monohidratado

Country Status (53)

Country Link
US (2) US20020013358A1 (es)
EP (1) EP1135381B1 (es)
JP (1) JP3777094B2 (es)
KR (1) KR100413739B1 (es)
CN (1) CN1131860C (es)
AP (1) AP2001002149A0 (es)
AR (1) AR024232A1 (es)
AT (1) ATE273300T1 (es)
AU (1) AU754731B2 (es)
BG (1) BG64706B1 (es)
BR (1) BR9915692A (es)
CA (1) CA2352392C (es)
CO (1) CO5150178A1 (es)
CR (1) CR6325A (es)
CU (1) CU23269A3 (es)
CZ (1) CZ295472B6 (es)
DE (1) DE69919388T2 (es)
DK (1) DK1135381T3 (es)
DZ (1) DZ2948A1 (es)
EA (1) EA003551B1 (es)
EE (1) EE04914B1 (es)
ES (1) ES2224701T3 (es)
GB (1) GB9825988D0 (es)
GC (1) GC0000113A (es)
GE (1) GEP20043183B (es)
GT (1) GT199900202A (es)
HK (1) HK1042898B (es)
HN (1) HN1999000196A (es)
HR (1) HRP20010398B1 (es)
HU (1) HUP0105308A3 (es)
ID (1) ID28802A (es)
IL (1) IL141663A (es)
IS (1) IS2238B (es)
MA (1) MA26708A1 (es)
MY (1) MY124078A (es)
NO (1) NO320798B1 (es)
NZ (1) NZ510055A (es)
OA (1) OA11671A (es)
PA (1) PA8485701A1 (es)
PE (1) PE20001299A1 (es)
PL (1) PL194503B1 (es)
PT (1) PT1135381E (es)
RS (1) RS50002B (es)
SI (1) SI1135381T1 (es)
SK (1) SK285774B6 (es)
SV (1) SV1999000204A (es)
TN (1) TNSN99221A1 (es)
TR (1) TR200101493T2 (es)
TW (1) TWI246512B (es)
UA (1) UA68402C2 (es)
UY (2) UY25823A1 (es)
WO (1) WO2000032589A1 (es)
ZA (1) ZA200102681B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
WO2004089365A1 (en) 2003-04-11 2004-10-21 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
EP2093225A1 (en) 2007-05-01 2009-08-26 Plus Chemicals B.V. Process for preparing crystalline eletriptan hydrobromide form ß
EP2038273A1 (en) * 2007-05-29 2009-03-25 Plus Chemicals B.V. A process for preparing 5-bromo-3-[(r)-1-methyl-pyrrolidin-2-ylmethyl]-1h-indole
US20100285075A1 (en) * 2007-12-17 2010-11-11 Actavis Group Ptc Ehf Novel Hemioxalate Salt of Eletriptan
US20120027816A1 (en) * 2009-02-25 2012-02-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
WO2011089614A1 (en) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
CN103893112A (zh) * 2012-12-31 2014-07-02 重庆圣华曦药业股份有限公司 氢溴酸依来曲普坦注射液
CN107954947A (zh) * 2016-10-14 2018-04-24 北京莱瑞森医药科技有限公司 沃替西汀氢溴酸盐晶型c及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
EP0592438B1 (en) 1990-10-15 1997-08-27 Pfizer Inc. Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9510223D0 (en) 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
AU724728B2 (en) 1997-07-03 2000-09-28 Pfizer Inc. Pharmaceutical compositions containing eletriptan hemisulphate and caffeine

Also Published As

Publication number Publication date
HRP20010398A2 (en) 2002-06-30
TR200101493T2 (tr) 2002-02-21
JP3777094B2 (ja) 2006-05-24
EA200100297A1 (ru) 2001-08-27
IL141663A (en) 2004-05-12
CN1131860C (zh) 2003-12-24
TNSN99221A1 (fr) 2005-11-10
HK1042898B (zh) 2004-10-08
EE04914B1 (et) 2007-10-15
AR024232A1 (es) 2002-09-25
AU6225399A (en) 2000-06-19
NO20012584D0 (no) 2001-05-25
BG105539A (en) 2001-12-29
CZ20011839A3 (cs) 2001-10-17
PA8485701A1 (es) 2000-09-29
EP1135381A1 (en) 2001-09-26
HN1999000196A (es) 2005-11-26
AP2001002149A0 (en) 2001-06-30
ATE273300T1 (de) 2004-08-15
CO5150178A1 (es) 2002-04-29
CA2352392A1 (en) 2000-06-08
PT1135381E (pt) 2004-10-29
SV1999000204A (es) 2000-10-16
TWI246512B (en) 2006-01-01
SK6992001A3 (en) 2002-01-07
CU23269A3 (es) 2008-04-09
MA26708A1 (fr) 2004-12-20
UY25823A1 (es) 2001-08-27
NO320798B1 (no) 2006-01-30
IS2238B (is) 2007-05-15
IS5868A (is) 2001-02-27
DE69919388T2 (de) 2005-09-29
IL141663A0 (en) 2002-03-10
EA003551B1 (ru) 2003-06-26
EP1135381B1 (en) 2004-08-11
GC0000113A (en) 2005-06-29
GB9825988D0 (en) 1999-01-20
KR100413739B1 (ko) 2004-01-03
GT199900202A (es) 2001-05-19
HUP0105308A3 (en) 2003-01-28
ID28802A (id) 2001-07-05
GEP20043183B (en) 2004-02-25
JP2002531449A (ja) 2002-09-24
ZA200102681B (en) 2002-07-02
AU754731B2 (en) 2002-11-21
PL194503B1 (pl) 2007-06-29
DK1135381T3 (da) 2004-11-15
NO20012584L (no) 2001-07-27
WO2000032589A1 (en) 2000-06-08
BG64706B1 (bg) 2005-12-30
SI1135381T1 (en) 2004-10-31
HK1042898A1 (en) 2002-08-30
CN1328554A (zh) 2001-12-26
UY25825A1 (es) 2000-08-21
UA68402C2 (en) 2004-08-16
YU18801A (sh) 2003-07-07
CA2352392C (en) 2006-01-24
BR9915692A (pt) 2001-08-14
US20050131237A1 (en) 2005-06-16
CR6325A (es) 2008-07-02
NZ510055A (en) 2004-11-26
KR20010080594A (ko) 2001-08-22
HRP20010398B1 (en) 2004-12-31
MY124078A (en) 2006-06-30
HUP0105308A2 (hu) 2002-05-29
DZ2948A1 (fr) 2004-03-15
US7238723B2 (en) 2007-07-03
US20020013358A1 (en) 2002-01-31
CZ295472B6 (cs) 2005-08-17
PL347928A1 (en) 2002-04-22
SK285774B6 (sk) 2007-08-02
ES2224701T3 (es) 2005-03-01
OA11671A (en) 2005-01-12
DE69919388D1 (de) 2004-09-16
EE200100285A (et) 2002-08-15
RS50002B (sr) 2008-09-29

Similar Documents

Publication Publication Date Title
PE20001299A1 (es) Bromhidrato de eletriptan monohidratado
PE20011167A1 (es) Composiciones farmaceuticas que comprenden un antagonista del alfa-adrenoreceptor y un antagonista muscarinico para el tratamiento de hiperplasia prostatica benigna
MA30652B1 (fr) Composes organiques
CO4950530A1 (es) Agonistas de receptores 5-ht, y metoclopramida para el tratamiento de la migrana
UY24543A1 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol- 3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona
PE20001483A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
PE20011178A1 (es) Compuestos heterociclicos y su produccion
MA29231B1 (fr) Nouveaux composes heterocycliques utiles pour le traitement de troubles inflammatoires et allergiques
PE20040608A1 (es) Compuestos de alquino con efecto antagonico de la hcm y medicamentos que los contienen
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
CA2194984A1 (en) 4-indole derivatives as serotonin agonists and antagonists
FI954944A (fi) Indolijohdannaisia 5-HT1-kaltaisina agonisteina käytettäväksi migreenin hoitoon
AR012660A1 (es) Uso de compuestos de quinazolina para la manufactura de un medicamento util para el tratamiento de enfermedades poliquisticas del rinon.
PE20001305A1 (es) Derivados de pirazolopiridina
TR200103178T2 (tr) İntegrinlerin reseptörlere bağlanmasını engelleyen karboksilik asit türevleri.
PE20060964A1 (es) Forma cristalina b de clorhidrato de (3-cian-1h-indol-7-il)-[4-(4-fluorofenetil)-piperazin-1-il]-metanona y procedimiento de preparacion
NO20015428L (no) Anvendelse av selektive antagonister for den <alfa>1b- adrenerge reseptor for forbedring av seksuell dysfunksjon
BR0208555A (pt) Sistema duplo de alimentação de produtos quìmicos sólidos
ES2128427T3 (es) Derivados condensados de imidazol y triazol como agonistas de receptores de 5-ht1.
PE20001583A1 (es) Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina
ATE218566T1 (de) Indol derivate als 5-ht1 agoniste
PE20060942A1 (es) Derivados nonadepsipeptidos acilados ii como agentes bactericidas
JP2003535050A5 (es)
PE20050950A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
PE20000413A1 (es) Ligandos azabiciclicos de receptores 5ht1

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed